Butyrylcholinesterase (BChE) is becoming an increasingly important drug target for alleviating the symptoms of Alzheimer's disease. Selective inhibition of BChE can successfully increase levels of acetylcholine in central nervous system and consequently improve the course of the disease. Based on the chemical structure of the compound 2, which is the first noncovalent selective BChE inhibitor with in vivo activity, we designed and synthesized ten new compounds to better understand the structure-activity relationship. Inhibitory potency was determined in vitro with the use of the method of Ellman. Eight out of ten synthesized compounds showed in vitro inhibitory activity against BChE. The most potent BChE inhibitor is compound 10 (IC50 = 0,21 μM). We determined that the naphthalene of compound 2 is essential for potent inhibition of BChE. At the same time, we were able to deepen the knowledge and further expand the structure-activity relationship of N-benzylpiperidines as selective BChE inhibitors.
|